Among patients with hormone receptor-positive breast cancer treated with an aromatase inhibitor plus Ibrance (palbociclib), those who displayed a rising ESR1 mutation detected in their blood before disease progression doubled their median progression-free survival following a switch to Faslodex (fulvestrant) plus Ibrance, according to results from the phase III PADA-1 clinical trial.
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure.
